Could a medicine called ONC-201 help treat children with T-cell acute lymphoblastic leukaemia?
Looking at whether a pre-existing drug could be an effective and safe treatment due to its ability to target cancer cells directly.
Studying the origins of childhood acute myeloid leukaemia to identify targets for kinder and more effective treatments
Learning more about leukaemia cells in order to design targeted treatments that can increase survivorship and quality of life.
Exploring new targeted therapy options for acute myeloid leukaemia in babies
Looking for repurposed treatments that can fight leukaemia cells in very young children.
Targeting a relapse causing protein to treat childhood acute myeloid leukaemia
Investigating how a protein that causes relapse in acute myeloid leukaemia interacts with the genetic code, and whether these interactions could be prevented.
Investigating why some children get leukaemia after treatment for other cancers
Looking at the early stages of leukaemia that develops after treatment for other cancers to find out what changes occur and how to fight it.
Finding out how infant leukaemia cells interact with the immune system
Understanding how leukaemia cells enlist immune system cells to help them survive chemotherapy.
Understanding how blood cancer develops and comes back after treatment in babies
Investigating how a protein changes the way leukaemia cells behave in babies.
How do DNA cutting errors lead to relapsed childhood leukaemia
Looking at how a process called 'cut-and-run' leads to genetic errors, and how those errors could be prevented in order to prevent relapse in childhood leukaemia.
Identifying a new blood cancer to improve the outlook for leukaemia patients
Looking at a new subtype of leukaemia, called CML-like Ph+ALL, to see how best to diagnose and treat it.